This is a renewal application for the Partnership for Excellence in Cancer Research between The University of Puerto Rico (UPR) and The University of Texas MD Anderson Cancer Center (MDACC). The Partnership proposes structured initiatives to further enhance the research infrastructure within these two institutions to reduce the burden of cancer health disparities. Funds granted in this award will be used to support two full and one pilot research projects. The first full project examines the role of West African ancestry in prostate cancer risk and aggressiveness. Pilot data show an association of several ancestral genetic markers, body mass index, and socioeconomic status with higher-grade prostate cancer. The second full project focuses on magnetic nanoparticle based hyperthermia for ovarian cancer. Pilot project data show a marked decrease in the associated tumor size when treated with nanoparticles. The pilot study is a smoking cessation intervention in oncology clinics. Together, these projects comprise a multidisciplinary research portfolio representing the T l to T3 stages of the translational research continuum. Partnership funds will also be used to: 1) enhance existing collaborations and establish new collaborations;2) restructure the training pipeline to include customized career development tracks for physicians, scientists and physician scientists interested in cancer medicine to accelerate the development of a critical mass of faculty for the UPR Comprehensive Cancer Center (UPRCCC);3) implement a cancer education curriculum;and 4) maintain and expand the Outreach Program, including core services and an outreach research project designed to reduce the burden of colorectal cancer among Puerto Ricans. Thus far, the Partnership has established a dynamic collaborative team that is working towards fortifying and stabilizing the developing infrastructure at the UPRCCC as evidenced by a newly constructed UPRCCC Research Center (opened 6/2009);the UPRCCC hospital will be completed in 2016. Funding for a second renewal is critical to cement and build on the substantial momentum and success achieved by the Partnership over the last ten years. The Partnership is poised to fulfill its long-term goal of positioning the UPRCCC to become a frontrunner in addressing health disparities that affect Hispanic populations across the cancer continuum (prevention, early detection, diagnosis, treatment and survivorship).

Public Health Relevance

This renewal seeks to foster and support an existing collaboration between the UPR and MDACC. By addressing differences in incidence, prevalence, mortality, and burden of cancer that exist among Hispanic populations in the US, the Partnership strives to reduce these disparities through efforts in Cancer Research, Training, Education and Outreach. Partnership contributions will also aid in building a stronger national cancer program through the development of a pipeline of well-trained, Hispanic cancer researchers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54CA096300-11
Application #
8609637
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (O1))
Program Officer
Ogunbiyi, Peter
Project Start
2002-08-16
Project End
2018-08-31
Budget Start
2013-09-25
Budget End
2014-08-31
Support Year
11
Fiscal Year
2013
Total Cost
$1,077,820
Indirect Cost
$360,964
Name
University of Texas MD Anderson Cancer Center
Department
Miscellaneous
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Bottsford-Miller, Justin; Choi, Hyun-Jin; Dalton, Heather J et al. (2015) Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res 21:602-10
Previs, Rebecca A; Coleman, Robert L; Harris, Adrian L et al. (2015) Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res 21:955-61
Cho, Min Soon; Vasquez, Hernan G; Rupaimoole, Rajesha et al. (2014) Autocrine effects of tumor-derived complement. Cell Rep 6:1085-95
Wu, Sherry Y; Lopez-Berestein, Gabriel; Calin, George A et al. (2014) RNAi therapies: drugging the undruggable. Sci Transl Med 6:240ps7
Alvarez-Berríos, Merlis P; Castillo, Amalchi; Rinaldi, Carlos et al. (2014) Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines. Int J Nanomedicine 9:145-53
Huang, Xuelin; Ning, Jing; Wahed, Abdus S (2014) Optimization of individualized dynamic treatment regimes for recurrent diseases. Stat Med 33:2363-78
Ortiz, Ana Patricia; Pérez-Irizarry, Javier; Soto-Salgado, Marievelisse et al. (2014) Human papillomavirus-related cancers among people living with AIDS in Puerto Rico. Prev Chronic Dis 11:E80
Quintás-Cardama, Alfonso; Choi, Sangbum; Kantarjian, Hagop et al. (2014) Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk 14:327-334.e8
Pradeep, Sunila; Kim, Seung W; Wu, Sherry Y et al. (2014) Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26:77-91
Tucker, Susan L; Gharpure, Kshipra; Herbrich, Shelley M et al. (2014) Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res 20:3280-8

Showing the most recent 10 out of 41 publications